PHARMACOTHERAPY IN MUSCLE DYSMORPHIC DISORDER: CLINICAL CONSIDERATIONS AND THE LIMITS OF EXTRAPOLATING EVIDENCE FROM BODY DYSMORPHIC DISORDER
Authors:
- Anna ŁęCzyckaAŁAnna ŁęCzycka
- Kinga ŁysakKŁKinga Łysak
- Kinga HaduchKHKinga Haduch
- Zuzanna MichalskaZMZuzanna Michalska
- Nicole Aleksandra Ordyczyńska-MardyłaNONicole Aleksandra Ordyczyńska-Mardyła
- Izabela Zuzanna StranzISIzabela Zuzanna Stranz
- Aleksandra StańczykASAleksandra Stańczyk
- Olga ChorążyOCOlga Chorąży
- Joanna StrzelczykJSJoanna Strzelczyk
- Amelia KęDzioraAKAmelia KęDziora
- Iga SuchtaISIga Suchta
Open Access
- 17 June 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Abstract
Background: Muscle dysmorphic disorder is a specifier of body dysmorphic disorder (BDD) characterized by a tenacious belief of insufficient muscularity. Although currently classified within BDD, muscle dysmorphism exhibits distinct clinical and behavioral features, constituting compulsive exercise, rigid dietary practices, and use of performance-enhancing substances. Aforementioned differences raise concerns regarding applicability of pharmacotherapeutic strategies derived from BDD studies to patients with muscle dysmorphism. The aim of the study is to critically evaluate the existing literature on pharmacotherapy in body dysmorphic disorder and assess its clinical applicability to muscle dysmorphic disorder, with considerations of diverging neurobiological, phenomenological, and behavioral distinction limiting direct generalizability. Methods: A broad literature search was conducted in three major databases: PubMed, Cochrane Library, and Google Scholar, utilizing search terms (“muscle dysmorphism” or “muscle dysmorphic disorder” or “bigorexia nervosa” or “body dysmorphic disorder”) and (“pharmacotherapy” or “treatment” or “medication” or “pharmaceutical”). References were screened for relevance, and a total of 20 studies published between 1996 and 2026 were included in the analysis. Results: This review evaluates and summarizes established pharmacological strategies used in the treatment of BDD and examines their potential relevance for muscle dysmorphic disorder. Selective serotonin reuptake inhibitors (SSRIs) remain the most consistently supported pharmacological intervention, demonstrating meaningful reductions in symptom severity across several studies. Additional treatments, including clomipramine and serotonin–noradrenaline reuptake inhibitors, have shown potential benefits in selected cases. Emerging therapeutic approaches, such as glutamatergic modulators, intranasal oxytocin, and psychedelic-assisted therapy, remain experimental. However, no clinical trials have specifically examined pharmacotherapy in muscle dysmorphic disorder. Conclusions: Pharmacological strategies developed for BDD may provide partial therapeutic benefit, important differences in clinical presentation and potential neurobiological mechanisms limit direct extrapolation to muscle dysmorphic disorder. Future research should prioritize clinically controlled randomized trials exploring targeted pharmacological treatments for this condition.Keywords
This publication has 24 references indexed in Scilit:
- A meta-analysis and systematic review examining efficacy, acceptability and patient retention in psychotherapy studies for the treatment of body dysmorphic disorderBody Image, 2026
- The Efficacy of Cognitive Behavioural Therapy in the Management of Body Dysmorphic Disorder: A Systematic Review and Meta‐AnalysisClinical Psychology & Psychotherapy, 2026
- Muscle dysmorphia in adolescents and young adultsThe Lancet Child & Adolescent Health, 2025
- Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysisPsychiatry Research, 2024
- Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorderJournal of Psychiatric Research, 2023
- Intranasal oxytocin alters amygdala-temporal resting-state functional connectivity in body dysmorphic disorder: A double-blind placebo-controlled randomized trialPsychoneuroendocrinology, 2019
- Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2016
- Clinical features of muscle dysmorphia among males with body dysmorphic disorderBody Image, 2005
- A Randomized Placebo-Controlled Trial of Fluoxetine in Body Dysmorphic DisorderArchives of General Psychiatry, 2002
- Clomipramine vs Desipramine Crossover Trial in Body Dysmorphic DisorderArchives of General Psychiatry, 1999